GlassScriptPhysician profile
Renee Malvestuto
NPI 1407217094
$5,083.88
in general payments reported to CMS, 2019-2025
24 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $521 · 2022: $495 · 2023: $645 · 2024: $1,908 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,067.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,096.06 | 2021-2025 | Lifevest |
| Abiomed | $497.97 | 2023-2025 | Impella |
| Cvrx, INC. | $472.92 | 2021-2025 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $432.77 | 2024-2025 | Assure Wcd |
| Abbott Laboratories | $402.25 | 2022-2025 | Esprit, Cardiomems, Assurity |
| Novartis Pharmaceuticals Corporation | $371.75 | 2023-2024 | |
| Boston Scientific Corporation | $272.96 | 2023-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $194.31 | 2021-2025 | Micra |
| Astrazeneca Pharmaceuticals LP | $185.06 | 2021-2024 | Farxiga |
| Cleerly, INC. | $180.34 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Alnylam Pharmaceuticals INC. | $167.50 | 2023-2024 | Onpattro, Amvuttra |
| Novo Nordisk INC | $124.99 | 2024 | |
| Impulse Dynamics (USA) INC. | $123.73 | 2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $118.11 | 2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $106.87 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $101.56 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $53.97 | 2024 | Uptravi, Opsumit |
| Lexicon Pharmaceuticals, INC. | $42.29 | 2024 | |
| Amgen INC. | $36.70 | 2024 | Repatha |
| Daiichi Sankyo INC. | $28.10 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $22.91 | 2024 | Arcalyst |
| Medicomp INC | $21.01 | 2023 | Telepatch Cardiac Monitor |
| Azurity Pharmaceuticals, INC. | $15.32 | 2024 | Edarbi |
| Scpharmaceuticals INC. | $14.43 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Malvestuto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.